Abstract:Background Systemic lupus erythematosus (SLE) patients exist an imbalance between CD4+CD25+FoxP3+ T regulatory (Treg) and IL-17-producing cells (Th17). Correction of this Treg/Th17 imbalance may have therapeutic impact for SLE patients. Our previous study demonstrated that bone marrow derived mesenchymal stem cells (BMSCs) from SLE patients are defective in immune modulation, which might be involved in Treg/Th17 imbalance and disease onset, but the mechanisms are not clear yet. The expression imbalance of microRNAs (miRNAs) can cause cell dysfunction, which participates in a variety of diseases development. As an important computer predicted target of let-7, interlukin-6 (IL-6) is an important negative immune regulatory factors secreted by BMSCs. Our previous experiments found that the expressions of let-7 are markedly down-regulated in SLE BMSCs by microRNA array analysis, and the synthesis of IL-6 is significantly higher in SLE BMSCs compared to normal controls. Objectives To investigate whether loss of let-7 could play its role in SLE BMSCs immune modulation defects by directly up-regulating IL-6 mRNA, which might contribute to Treg/Th17 imbalance in PBMCs from SLE patients, to further understand the pathogenesis of SLE. Methods BMSCs were isolated, cultured and expanded from iliac crest bone marrow of four healthy donors and four SLE patients. Real-time PCR was used to further determine the let-7 expression and IL-6 mRNA level in BMSCs from healthy controls and SLE patients. The important computer predicted target of let-7, IL-6 was determined using the luciferase reporter assay. Let-7-mimics, let-7-inhibitor, and let-7-negative control were transfected to BMSCs with using Lipofectamine 2000. BMSCs from healthy controls and SLE patients were co-cultured with PBMCs from SLE patients for 72 hours to detect their effect on the ratio of Treg/Th17. Results Compared to normal controls, the expression of let-7 was markedly down-regulated in BMSCs from SLE patients by RT-PCR, and the synthesis of IL-6 mRNA and protein levels were significantly higher in BMSCs from SLE patients. Compared to let-7-negative controls, transfection of BMSCs with let-7-mimics markedly lower synthesis of TGF-β1 mRNA, and let-7-inhibitor led to an opposite effect. The mean value of Treg/Th17 was significantly decreased in PBMCs from SLE patients compared to normal controls. Transfection of normal BMSCs with let-7-inhibitor caused significant downregulation of Treg/Th17 compared to let-7-negative controls, while transfection with let-7-mimics led to an opposite effect. Conclusions SLE patients exist an imbalance between Treg and Th17 cells, which might be associated with up-regulation of IL-6 secretion of BMSCs by loss of let-7. Disclosure of Interest None declared

Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Enhanced Apoptosis And Senescence Of Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus

Study on Bone Marrow Mesenchymal Stem Cells in Systemic Lupus Erythematosus

Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus.

Abnormality of multilineage difierentiation potential of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

AB0160 Loss of Let-7 Microrna Upregulates Il-6 in Bone Marrow-Derived Mesenchymal Stem Cells Triggering Treg/th17 Imbalance in Patients with Systemic Lupus Erythematosus

Apoptosis of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythem atosus

Correlation of Cytokine Expression in Bone Marrow-Derived Mesenchymal Stem Cells with Activity of Systemic Lupus Erythematosus

Gene expression profile of peripheral blood B cells from patients with systemic lupus erythematosus using oligonucleotide DNA microarray

Gene profiling involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus

Abnormal surface markers expression on bone marrow CD34 + cells and correlation with disease activity in patients with systemic lupus erythematosus

Characterization of the ultrastructure and cytoskeleton of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

Biological Characteristics and Hematopoietic Support of Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus

Analysis of Gene Expression Profiles in Human Systemic Lupus Erythematosus Using Oligonucleotide Microarray

Association of bone marrow mesenchymal stem cells and intracellular reactive oxygen species levels in patients with systemic lupus erythematosus

Role of Olf-1/EBF associated zinc finger protein gene in bone marrow mesenchymal stem cells of systemic lupus erythematosus patients

Overexpression of miR-20a-5p in mesenchymal stem cell derived-exosomes from systemic lupus erythematosus patients restored therapeutic effect and Treg immune regulation

Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop

Migration and proliferation of human mesenchymai stem cells from patients with systemic lupus erythematosus mediated by IKK-β